KWMG
AVDL

King Wealth Management Group’s Avadel Pharmaceuticals AVDL Stock Holding History

King Wealth Management Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$305K – 166
2025
Q3 		$305K Sell
20,000
-15,000
-43% -$195K 0.04% 129
2025
Q2 		$310K Hold
35,000
– – 0.04% 126
2025
Q1 		$274K Hold
35,000
– – 0.04% 128
2024
Q4 		$368K Buy
+35,000
New +$425K 0.05% 106

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

King Wealth Management Group's AVDL Position: Q4 2025 in Review

King Wealth Management Group sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 20,000 shares — an estimated $305K sold.

King Wealth Management Group first reported a position in AVDL in Q4 2024 and held it in 4 quarters. The position peaked at $368K in Q4 2024. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • King Wealth Management Group reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • King Wealth Management Group sold 20,000 Avadel Pharmaceuticals shares in Q4 2025, an estimated $305K.
  • King Wealth Management Group first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • King Wealth Management Group's Avadel Pharmaceuticals position peaked at $368K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on King Wealth Management Group's 13F filing for Q4 2025, filed 9 Feb 2026.